Profile data is unavailable for this security.
About the company
Context Therapeutics Inc. is a biopharmaceutical company advancing medicines for solid tumors. The Company is developing CTIM-76, a selective Claudin 6 (CLDN6) x CD3 bispecific antibody for CLDN6-positive tumors, which is in preclinical development. CLDN6 is a tight junction membrane protein target expressed in multiple solid tumors, including ovarian, endometrial, testicular, and lung, and absent from or expressed at low levels in healthy adult tissues. CTIM-76 is capable of binding to tumor cells expressing CLDN6 and stimulating intra-tumoral T cells by the CD3 arm that is designed to be activated only upon tumor engagement while silent elsewhere. CTIM-76 has the potential for a wide therapeutic window, which is the difference between the dose required for the intended therapeutic effect and the dose required to elicit an unwanted side effect.
- Revenue in USD (TTM)0.00
- Net income in USD-21.32m
- Incorporated2015
- Employees5.00
- LocationContext Therapeutics Inc2001 Market Street, Suite 3915 Unit #15PHILADELPHIA 19103United StatesUSA
- Phone+1 (267) 225-7416
- Fax+1 (302) 655-5049
- Websitehttps://www.contexttherapeutics.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| aTyr Pharma Inc | 588.00k | -53.93m | 138.02m | 56.00 | -- | 1.62 | -- | 234.73 | -0.9029 | -0.9029 | 0.0099 | 1.24 | 0.0047 | -- | 0.2868 | 10,500.00 | -43.13 | -45.45 | -48.85 | -52.74 | -- | -- | -9,172.11 | -784.19 | -- | -- | 0.021 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Seres Therapeutics Inc | 126.85m | -82.68m | 139.32m | 233.00 | -- | -- | -- | 1.10 | -0.6062 | -0.6062 | 0.9495 | -0.3945 | 0.4149 | -- | -- | 544,407.80 | -27.04 | -41.51 | -36.82 | -54.13 | -- | -- | -65.18 | -170.14 | 1.25 | -9.21 | 2.41 | -- | 1,672.24 | 34.91 | 54.54 | -- | 32.72 | -- |
| Rapt Therapeutics Inc | 0.00 | -118.05m | 140.59m | 126.00 | -- | 1.07 | -- | -- | -3.07 | -3.07 | 0.00 | 3.76 | 0.00 | -- | -- | 0.00 | -58.42 | -46.30 | -65.33 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| I-Mab ADR | 3.83m | -202.91m | 141.55m | 220.00 | -- | 0.5937 | -- | 36.99 | -2.44 | -2.44 | 0.046 | 2.95 | 0.0083 | -- | -- | 17,395.48 | -43.84 | -35.99 | -53.14 | -42.08 | 100.00 | -- | -5,302.03 | -496.71 | -- | -42.63 | 0.0171 | -- | 112.48 | -12.46 | 41.54 | -- | -4.66 | -- |
| Renovaro Inc | 0.00 | -53.93m | 143.08m | 11.00 | -- | 0.8486 | -- | -- | -0.7661 | -0.7661 | 0.00 | 1.14 | 0.00 | -- | -- | 0.00 | -37.06 | -27.81 | -41.75 | -28.44 | -- | -- | -- | -- | -- | -24.38 | 0.0405 | -- | -- | -- | 65.02 | -- | -0.1538 | -- |
| Corvus Pharmaceuticals Inc | 0.00 | -24.86m | 143.24m | 28.00 | -- | 3.37 | -- | -- | -0.5113 | -0.5113 | 0.00 | 0.6804 | 0.00 | -- | -- | 0.00 | -50.58 | -38.31 | -59.70 | -43.34 | -- | -- | -- | -- | -- | -12.88 | 0.00 | -- | -- | -- | 34.57 | -- | -37.45 | -- |
| Elite Pharmaceuticals Inc | 47.32m | 15.55m | 145.54m | 53.00 | 9.37 | 3.14 | 8.61 | 3.08 | 0.0153 | 0.0153 | 0.0465 | 0.0456 | 0.7428 | 2.24 | 4.39 | 892,785.50 | 24.41 | 3.53 | 30.62 | 4.61 | 45.82 | 46.10 | 32.87 | 4.41 | 1.19 | 1.18 | 0.1449 | 0.00 | 5.87 | 35.57 | -59.97 | -- | 83.62 | -- |
| Syros Pharmaceuticals Inc | 6.98m | -144.49m | 145.67m | 68.00 | -- | 9.67 | -- | 20.87 | -5.01 | -5.01 | 0.2244 | 0.5633 | 0.0411 | -- | -- | 102,661.80 | -84.98 | -54.44 | -103.51 | -64.32 | -- | -- | -2,069.80 | -772.82 | -- | -- | 0.7332 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| CytomX Therapeutics Inc | 119.18m | 16.53m | 147.27m | 120.00 | 9.56 | -- | 7.93 | 1.24 | 0.1978 | 0.1978 | 1.53 | -0.4649 | 0.5684 | -- | 16.71 | 993,150.00 | 7.89 | -21.53 | 26.77 | -32.32 | -- | -- | 13.87 | -100.38 | -- | -- | -- | -- | 90.38 | 11.21 | 99.43 | -- | -26.01 | -- |
| Sagimet Biosciences Inc | 2.00m | -27.88m | 147.45m | 10.00 | -- | 1.16 | -- | 73.72 | -1.31 | -1.31 | 0.0937 | 3.98 | -- | -- | -- | 200,000.00 | -- | -- | -- | -- | -- | -- | -1,393.80 | -- | -- | -- | 0.00 | -- | -- | -- | 8.60 | -- | -- | -- |
| Context Therapeutics Inc | 0.00 | -21.32m | 150.00m | 5.00 | -- | 3.78 | -- | -- | -1.34 | -1.34 | 0.00 | 0.5288 | 0.00 | -- | -- | 0.00 | -99.14 | -- | -114.72 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -61.53 | -- | -- | -- |
| Repare Therapeutics Inc | 97.86m | -45.69m | 150.68m | 179.00 | -- | 0.644 | -- | 1.54 | -1.10 | -1.10 | 2.30 | 5.51 | 0.3265 | -- | 9.22 | 546,698.30 | -15.25 | -23.40 | -18.73 | -26.37 | -- | -- | -46.69 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| X4 Pharmaceuticals Inc | 0.00 | -128.91m | 155.91m | 93.00 | -- | 150.50 | -- | -- | -0.6968 | -0.6968 | 0.00 | 0.0062 | 0.00 | -- | -- | 0.00 | -108.98 | -61.53 | -133.20 | -69.20 | -- | -- | -- | -13,288.93 | -- | -- | 0.9815 | -- | -- | -- | -4.93 | -- | 12.03 | -- |
| Gossamer Bio Inc | 0.00 | -172.58m | 157.00m | 135.00 | -- | 5.88 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
| ProQR Therapeutics NV | 14.66m | -29.18m | 157.83m | 157.00 | -- | 4.32 | -- | 10.76 | -0.3594 | -0.3594 | 0.1806 | 0.4493 | 0.0957 | -- | -- | 93,385.40 | -18.83 | -35.51 | -23.01 | -40.51 | -- | -- | -196.75 | -926.31 | -- | -- | 0.3557 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Mediwound Ltd | 18.69m | -6.72m | 161.17m | 100.00 | -- | 4.96 | -- | 8.63 | -0.768 | -0.768 | 2.07 | 3.43 | 0.3209 | 6.28 | 2.87 | 186,860.00 | -11.53 | -24.48 | -14.35 | -32.92 | 19.15 | 43.27 | -35.94 | -38.43 | 4.33 | -- | 0.1674 | -- | -29.48 | 40.60 | 65.73 | -- | 64.66 | -- |
Data as of May 17 2024. Currency figures normalised to Context Therapeutics Inc's reporting currency: US Dollar USD
24.30%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Avidity Partners Management LPas of 02 May 2024 | 7.78m | 10.37% |
| Deep Track Capital LPas of 02 May 2024 | 7.42m | 9.89% |
| Opaleye Management, Inc.as of 31 Mar 2024 | 1.11m | 1.48% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 598.30k | 0.80% |
| Affinity Asset Advisors LLCas of 31 Mar 2024 | 328.82k | 0.44% |
| UBS O'Connor LLCas of 31 Mar 2024 | 296.68k | 0.40% |
| swisspartners AGas of 30 Jun 2023 | 260.00k | 0.35% |
| Adar1 Capital Management LLCas of 31 Mar 2024 | 205.93k | 0.28% |
| HighTower Advisors LLCas of 31 Mar 2024 | 125.85k | 0.17% |
| Bridgeway Capital Management LLCas of 31 Mar 2024 | 105.81k | 0.14% |
More ▼
Data from 30 Jun 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
